Buy Moderna Stock Before Q3 Earnings? Here's What to Know
Moderna (MRNA) is set to report Q3 2026 earnings on Nov 6, with sales and EPS estimates at $888.8M and -$1.37 respectively, both down year-over-year. The company's Earnings ESP is -71.32%, suggesting a potential miss. Key products include COVID-19, flu, and RSV vaccines, with oncology pipeline updates expected. MRNA stock has surged 652% YTD, trading at a premium valuation.
How this was made
The 30-second read
Why it matters
The trading focus is the pre-earnings setup: consensus implies year-over-year declines, while the model flags unfavorable odds for a beat (negative Earnings ESP). The article also highlights that commercial traction for oncology is still a longer-dated risk.
Market read
Provides concrete consensus numbers and a model-based earnings-beat probability framing that can inform positioning into the Nov. 6 open.
What to watch
The piece focuses on the earnings beat odds model and valuation premium, but does not quantify how much oncology pipeline updates or respiratory product mix could change near-term expectations.
Background
Zacks previews Moderna’s Q3 2026 earnings (Nov. 6 pre-market) and discusses consensus estimates, recent earnings surprise history, and pipeline context around intismeran with Merck.
Ticker impact
Moderna is set to report Q3 2026 earnings Nov. 6, with consensus sales at $888.8M and EPS loss at $1.37.
Likely two-sided reaction, but downside risk if results or guidance disappoint versus the already-negative consensus framing.
The piece provides specific pre-earnings consensus figures and highlights a negative Earnings ESP (-71.32%), implying the market may already be leaning cautious.
Market effects
Reinforces biotech earnings sensitivity to valuation and pipeline-to-commercial translation, especially for mRNA oncology narratives.
No direct regional market catalyst beyond US biotech earnings season positioning.
Limited, as the main driver is a US-listed company’s earnings timing and consensus expectations.
Counterpoint
Despite the negative Earnings ESP, the article notes Moderna has beaten estimates in 3 of the last 4 quarters, which can support a surprise if pipeline commentary offsets near-term losses.
Key entities
- companyModerna
US-listed mRNA therapeutics company scheduled to report Q3 2026 earnings on Nov. 6 before the open.
- companyMerck
Partner on intismeran (personalized mRNA cancer therapy) being evaluated with Keytruda.
- companyGSK
Referenced as marketing RSV vaccine Arexvy, cited as competitive pressure for mResvia.
- companyPfizer
Referenced as marketing RSV vaccine Abrysvo, cited as competitive pressure for mResvia.
